OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EHCNYSE65

Encompass Health Corp

Healthcare Facilities & ServicesVerified

Capital Structure and Liquidity Encompass Health Corp maintains a debt-to-equity ratio of 1.0, indicating a balanced capital structure. The company's liquidity position is characterized by a current ratio of 1.08, which is near the minimum comfort range. Despite having $72.2 million in cash and equivalents, the company's net cash position is negative after accounting for total debt. ### Profitability and Returns The company's return on equity (ROE) is 23.22%, significantly outperforming the industry median for Healthcare Facilities & Services, which typically ranges between 10-15%. Return on assets (ROA) stands at 7.99%, which is also above the industry median of 5-7%. These metrics suggest strong operational efficiency and effective use of capital. ### Segments and Geographic Exposure Encompass Health Corp's revenue is concentrated in its inpatient rehabilitation hospital services, with no disclosed geographic diversification in the provided data. The company's strategy focuses on expanding its network of hospitals and strengthening relationships with healthcare systems, which may increase revenue concentration risks. ### Growth Trajectory The company's FY2025 revenue of $5.94 billion reflects a growth trajectory supported by capacity expansions and new hospital developments. The company's strategy to expand its network and add capacity to existing hospitals is expected to drive future revenue growth. ### Risk Factors Key risk factors include the current ratio being near the minimum comfort range and the potential for dilution due to missing basic and diluted share counts. The company's leverage and liquidity profiles are considered strong, mitigating exposure to interest rate volatility and near-term refinancing risks. ### Recent Events Recent events include the issuance of ASU 2025-06 by the FASB, which introduces targeted improvements to the accounting for internal-use software. The company also reported no impairment charges related to its debt securities during the three and nine months ended September 30, 2025.

30-day price · EHC+8.39 (+8.6%)
Low$94.98High$109.89Close$106.10As of18 May, 00:00 UTC
Profile
CompanyEncompass Health Corp
ExchangeNYSE
TickerEHC
CIK0000785161
SICServices-Hospitals
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Encompass Health Corp operates inpatient rehabilitation hospitals and provides post-acute healthcare services, generating revenue primarily through patient care services and capacity expansions.

Classification. Encompass Health Corp is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

### Capital Structure and Liquidity Encompass Health Corp maintains a debt-to-equity ratio of 1.0, indicating a balanced capital structure. The company's liquidity position is characterized by a current ratio of 1.08, which is near the minimum comfort range. Despite having $72.2 million in cash and equivalents, the company's net cash position is negative after accounting for total debt. ### Profitability and Returns The company's return on equity (ROE) is 23.22%, significantly outperforming the industry median for Healthcare Facilities & Services, which typically ranges between 10-15%. Return on assets (ROA) stands at 7.99%, which is also above the industry median of 5-7%. These metrics suggest strong operational efficiency and effective use of capital. ### Segments and Geographic Exposure Encompass Health Corp's revenue is concentrated in its inpatient rehabilitation hospital services, with no disclosed geographic diversification in the provided data. The company's strategy focuses on expanding its network of hospitals and strengthening relationships with healthcare systems, which may increase revenue concentration risks. ### Growth Trajectory The company's FY2025 revenue of $5.94 billion reflects a growth trajectory supported by capacity expansions and new hospital developments. The company's strategy to expand its network and add capacity to existing hospitals is expected to drive future revenue growth. ### Risk Factors Key risk factors include the current ratio being near the minimum comfort range and the potential for dilution due to missing basic and diluted share counts. The company's leverage and liquidity profiles are considered strong, mitigating exposure to interest rate volatility and near-term refinancing risks. ### Recent Events Recent events include the issuance of ASU 2025-06 by the FASB, which introduces targeted improvements to the accounting for internal-use software. The company also reported no impairment charges related to its debt securities during the three and nine months ended September 30, 2025.
Key takeaways
  • Encompass Health Corp demonstrates strong profitability with a ROE of 23.22% and ROA of 7.99%.
  • The company's liquidity position is near the minimum comfort range, with a current ratio of 1.08.
  • Revenue is concentrated in inpatient rehabilitation hospital services, with no disclosed geographic diversification.
  • The company's strategy to expand its network and add capacity is expected to drive future revenue growth.
  • Key risk factors include the current ratio and potential dilution risks.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$5.94B
Gross profit
Operating income
Net income$566.2M
R&D
SG&A$236.2M
D&A$327.9M
SBC$56.5M
Operating cash flow
CapEx
Free cash flow
Total assets$7.09B
Total liabilities$3.81B
Total equity$2.44B
Cash & equivalents$72.2M
Long-term debt$2.45B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$5.94B$566.2M
FY2024$5.37B$455.7M
FY2025$5.37B$455.7M
FY2023$4.80B$352.0M
FY2024$4.80B$352.0M
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$7.09B$2.44B$72.2M
FY2024$6.53B$2.07B$85.4M
FY2025$6.53B$2.07B$85.4M
FY2023$6.10B$1.65B$69.1M
FY2024$6.10B$1.65B$69.1M
PeriodOCFCapExFCFSBC
FY2025$56.5M
FY2024$48.3M
FY2025$48.3M
FY2023$50.6M
FY2024$50.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$4.39B$420.1M
Q2 2025$2.91B$293.6M
Q3 2025
Q1 2025$1.46B$151.5M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$6.87B$2.37B$48.7M
Q2 2025$6.79B$2.28B$99.1M
Q3 2025$3.03B
Q1 2025$6.64B$2.16B$95.8M
PeriodOCFCapExFCFSBC
Q3 2025$38.1M
Q2 2025$23.8M
Q3 2025
Q1 2025$9.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.65B
Net cash-$2.38B
Current ratio1.1
Debt/Equity1.0
ROA8.0%
ROE23.2%
Cash conversion
CapEx/Revenue
SBC/Revenue0.9%
Asset intensity
Dilution ratio
Risk assessment
Dilution riskUnknown
Liquidity riskHigh
  • Current ratio is close to the minimum comfort range.
  • Net cash is negative after subtracting total debt.
  • Dilution risk could not be assessed (basic + diluted share counts missing).
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricEHCActivity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin9.5%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue4.9% medp25 4.2% · p75 6.3%
Debt / equity100.0%71.3% medp25 19.0% · p75 91.7%top quartile
Observations
IR observations
market data ESG controversies score84.2
market data ESG governance pillar68.0
market data ESG social pillar46.9
market data insider trading score2.0
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 11:22 UTCJob: 7feec082